publication venue for
- Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.. 6. 2024
- Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testing.. 5. 2023
- Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors.. 4. 2022
- Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis.. 3. 2021
- Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer.. 3. 2021
- Advances in the diagnosis, evaluation, and management of leptomeningeal disease.. 3. 2021
- Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.. 3. 2021
- Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center.. 3. 2021
- [68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas.. 3. 2021
- Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study.. 3. 2020
- Tumor edge-to-core transition promotes malignancy in primary-to-recurrent glioblastoma progression in a PLAGL1/CD109-mediated mechanism.. 2. 2020
- Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR.. 2. 2020
- Missing diversity in brain tumor trials.. 2. 2020
- Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab.. 2. 2020
- A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria.. 2. 2020
- Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.. 2. 2020
- Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy.. 1. 2019
- A multidisciplinary management algorithm for brain metastases. 2022
- Standard clinical approaches and emerging modalities for glioblastoma imaging. 2022
- Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT). 2022